RNA: Philly drug developer Aro to get $1.4 billion if it meets Ionis’ targets
U City start-up Aro Biotherapeutics sets targets to deliver RNA drugs
Skip to contentDr. Sue Dillon, ceo and cofounder, Aro Biotherapeutics
U City start-up Aro Biotherapeutics sets targets to deliver RNA drugs